Theron Pharmaceuticals
- Company typePrivate
- Founded2008
- HeadquartersSunnyvale, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Theron Pharmaceuticals firmographics
Firmographics- Name
- Theron Pharmaceuticals
- Website
- https://theronpharma.com
- Company type
- Private
- Founded year
- 2008
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Theron Pharmaceuticals industry classification
Industry- Product category
- Respiratory Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Theron Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Sunnyvale
- HQ country
- United States
- HQ region
- North America
Markets served
Theron Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Theron Pharmaceuticals product offering
Product offeringCore offering
Theron Pharmaceuticals is a biotechnology company that develops therapeutic products for the treatment of chronic respiratory diseases. The company engages in pharmaceutical research and development activities focused on pulmonary conditions, operating with a small team from Sunnyvale, California.
Differentiator
Problem solved
Functional benefit
Products and services
- Therapeutic products for chronic respiratory diseases
Companies that use Theron Pharmaceuticals
Customer profileIdeal customer profiles1 record
Theron Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Theron Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: Major pharma with a large respiratory and immunology franchise (Symbicort, Fasenra, Trixeo), the leading large-cap competitor in chronic respiratory therapeutics.
- Boehringer Ingelheim: Private global pharmaceutical company with a leading respiratory portfolio (Spiriva, OFEV), representing the broad incumbent benchmark for chronic respiratory therapeutics.
- GSK: Global pharmaceutical leader with a dominant respiratory franchise (Trelegy, Nucala, etc.), the primary commercial incumbent in chronic respiratory therapeutics.
Direct peers
- Theravance Biopharma: Specialty biopharma with respiratory disease programs including treatments for COPD and asthma, sharing Theron's therapeutic area and small-cap specialty positioning.
- Pulmatrix: Clinical-stage respiratory therapeutics company developing inhaled therapies for chronic respiratory diseases, a direct functional comparator to Theron's focus.
- Insmed: Late-stage respiratory and rare disease biopharma, comparable as a focused respiratory therapeutics developer with inhaled and pulmonary programs.
- Verona Pharma: Specialty respiratory therapeutics developer focused on COPD and other chronic respiratory diseases, directly comparable to Theron's stated therapeutic focus.
- Avalo Therapeutics: Small-cap clinical-stage biotech with respiratory and immunology assets, comparable in therapeutic focus and company scale.
Emerging players
- ProQR Therapeutics: Clinical-stage biotech developing RNA-based therapeutics for rare pulmonary and respiratory diseases such as cystic fibrosis, comparable as a small-cap respiratory-focused developer.
- Mereo BioPharma: Clinical-stage specialty biotech with respiratory and rare disease programs, comparable as a small specialty respiratory developer.
Market position
Customer concentration
Theron Pharmaceuticals social profiles
Digital presenceTheron Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Theron Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Theron Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Theron Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Theron Pharmaceuticals
What does Theron Pharmaceuticals do?
Theron Pharmaceuticals is a biotechnology company that develops therapeutic products for the treatment of chronic respiratory diseases. The company engages in pharmaceutical research and development activities focused on pulmonary conditions, operating with a small team from Sunnyvale, California.
When was Theron Pharmaceuticals founded?
Theron Pharmaceuticals was founded in 2008. It employs 1 to 10 people.
Where is Theron Pharmaceuticals based?
Theron Pharmaceuticals is headquartered in Sunnyvale, United States, in the North America region.
Who are Theron Pharmaceuticals's main competitors?
Broad incumbents on record are AstraZeneca, Boehringer Ingelheim and GSK. Direct peers are Theravance Biopharma, Pulmatrix, Insmed, Verona Pharma and Avalo Therapeutics. Emerging players are ProQR Therapeutics and Mereo BioPharma.
Does Theron Pharmaceuticals have an API?
No public API is recorded for Theron Pharmaceuticals.
What industry is Theron Pharmaceuticals in?
Theron Pharmaceuticals's product category is Respiratory Therapeutics. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.